Underpayment Patterns in Buy-and-Bill Biologic Remittances

Buy-and-bill biologic remittances underpay practices in patterns that repeat, quarter after quarter, payer after payer. The money doesn't vanish through denials. It vanishes through paid claims that look clean on the surface but pay less than the contract, the ASP, or the correct unit count says they should.

The sequence is simple to describe and expensive to get wrong. A practice buys the drug from a distributor, gives it to the patient, submits the claim, and waits. That wait is the exposure window. Drug cost hits the practice's books the moment it's purchased and administered. Reimbursement shows up weeks later, if it shows up correctly at all. Any gap between what the payer pays and what the contract actually requires lands directly against inventory that's already gone into a patient and can't be put back on a shelf.

Medicare Part B sets the baseline at 106% of ASP, or ASP+6%, though sequestration cuts that to roughly ASP+4.3% in practice. That's a thin margin by design, meant to cover overhead and a sliver of profit, not to absorb billing mistakes. Commercial payers negotiate their own markups, and the spread runs wide: around 13% for office-based practices, but as high as 148% for hospital-based clinicians. So the damage from an underpayment depends heavily on payer mix and site of care. A biologic claim isn't one number to get right, either. It bundles the drug cost (J-code, units, NDC), the administration code (governed by CPT hierarchy), and the medical necessity documentation (ICD-10) into a single encounter. Each piece is its own place for money to leak.

And when it leaks, it doesn't look like a leak. Payers post underpayments as contractual adjustments, the same label used for legitimate write-offs. In an aggregate remittance view, a correct write-off and a wrong one look identical. Rheumatology practices carry outsized risk here: infusion therapy billing can run 40% of revenue, with average monthly biologic cost per patient exceeding $15,000. When that much revenue sits inside a category this prone to quiet underpayment, the exposure compounds fast.

How ASP-based rate errors produce systematic underpayment

CMS recalculates ASP every quarter based on manufacturer-reported sales data. If a payer is still running last quarter's rate against this quarter's claims, every one of those claims underpays by a fixed, calculable amount, and it keeps happening until someone notices. The pattern is systematic. The recovery is possible. Neither one happens automatically.

Practices can't assume a J-code's reimbursement rate from six months ago still holds today. ASP monitoring has to run continuously, because when a payer's fee schedule lags behind the current quarter, every claim for that drug in that period underpays by the same delta, drug after drug, patient after patient.

The math gets serious fast with high-cost biologics. Bevacizumab (J9035), rituximab (J9312), pembrolizumab (J9271): even a small per-unit ASP error multiplies across every unit billed and every patient treated that quarter. A five-cent-per-unit discrepancy on a drug billed in hundreds of units, across dozens of patients, adds up to real money before anyone catches it.

A structural shift is coming, and it deserves attention now rather than after it lands. CMS's GLOBE and GUARD mandatory models, proposed in the Federal Register on December 23, 2025, would layer a "most-favored nation" rebate mechanism on top of ASP+6% for certain drugs, pending finalization. GLOBE's performance period is set to begin October 1, 2026, and GUARD's January 1, 2027. If finalized, the effect would push net reimbursement toward international benchmark prices. If those benchmarks sit below the domestic acquisition cost. acquisition cost, practices lose money on every single administration, and the underpayment risk shifts from a payer error to a matter of federal policy.

Biosimilars add another wrinkle. Starting in 2025, Medicare pays biosimilars at ASP+8% for the first five years after launch, two points richer than the ASP+6% reference rate. A practice that isn't tracking which NDCs qualify for that higher rate may sit there accepting ASP+6% payments when it's owed more. These errors are recoverable inside filing and appeal windows, but they're invisible without a mechanism that checks the rate actually paid against the correct quarterly ASP, at the J-code level, every single time.

Unit calculation errors and J-code descriptor misapplication

Every J-code descriptor specifies an exact unit: per 10 mg, per 1 mg, whatever the drug calls for. Payers price and pay against that unit. Bill fewer units than what was actually given, and the underpayment is direct and mechanical, recoverable only if someone catches it.

Weight-based dosing in oncology and rheumatology makes this worse. Dose varies patient to patient, so rounding down instead of up, or missing a dose adjustment mid-treatment, quietly undercodes the claim. The error usually isn't born at the billing desk, either. It starts at the coding or nursing documentation step. If the chart doesn't capture the administered dose with enough precision, the biller has no way to reconstruct the right unit count later.

Unit errors are dangerous because they appear in remittance data as paid claims, not denials, and a paid claim sails through remittance review without raising a flag. Nobody's hunting for a problem in something that already says "paid."

The highest-stakes J-codes for this kind of error include bevacizumab (J9035), rituximab (J9312), infliximab (J1745), adalimumab, and IVIG products (J1459, along with other IVIG J-codes). The dollar amounts per unit run high enough that a single miscounted infusion can mean thousands of dollars gone, with no denial trail to chase.

Undercoding units costs revenue quietly. Overcoding creates overpayment liability and audit exposure loudly. Both trace back to the same root, a documentation gap, but only undercoding hides inside the remittance. Overcoding tends to get caught, eventually, by someone on the payer's side. That is why undercoding is the one that should worry a practice more.

One more coding trap sits nearby: the unclassified drug code, J3490. Defaulting to it when a specific J-code exists, or picking the wrong specific code, triggers manual payer review and often ends in payment at a reduced or generic rate. That's underpayment born from a coding decision, not a math error, but the financial effect lands the same.

Bundling reductions and NCCI edits that compress drug and administration payment

Multi-drug infusion encounters, common in oncology and rheumatology with three to five agents in a single visit, run on a strict hierarchy. One CPT code is primary, others are sequential or concurrent, and the sequencing has to be right or NCCI edits fire automatically.

Get the hierarchy wrong on the practice's end, and the result is a bundling adjustment or denial, lost administration revenue the practice actually earned. But payers make mistakes too, applying overly aggressive NCCI edits to a claim that was coded correctly from the start. When that happens, the adjustment posts as a routine contractual reduction and goes unchallenged, because it looks exactly like every other standard edit.

CO-97 denials are a specific version of this problem. The payer treats the drug as already included in the administration payment and denies the J-code line as "bundled," even when the drug is separately payable under the payer's own contract. Add a mismatched CPT and J-code, say an IV drug code paired with a subcutaneous injection CPT, or administration units multiplied against drug milligrams instead of dose units, and the claim structure becomes something a payer can partially deny without the error ever looking obvious on the remittance.

Modifiers matter here too. Missing a JW (drug wasted) or JZ (no drug wasted) modifier on an applicable Part B drug claim can trigger a denial or a payment cut, and the requirement applies line by line, not encounter by encounter.

Watch for this pattern: bundling underpayments run payer-specific. One payer bundles a CPT pair that another pays separately without blinking. That inconsistency is why these errors stay invisible unless remittances get reviewed payer by payer, code by code, not lumped into an aggregate view.

Biosimilar substitution pricing and its selective application by payers

Some payers reprice a branded biologic claim at the biosimilar's lower ASP, even when the practice bought and administered the branded product. The practice still absorbed the branded acquisition cost. The payer pays as though a cheaper drug went into the patient's arm. That gap is pure underpayment against what the drug actually cost.

This isn't automatically a contract violation, and treating it as one without checking the paperwork wastes time. Some payer contracts explicitly allow biosimilar substitution pricing; others don't. Figuring out which requires reading the contract closely rather than skimming the remittance.

Medicare's 2025 shift to ASP+8% for biosimilars versus ASP+6% for reference biologics flips the usual direction in some categories. The biosimilar can now pay more per unit than the branded drug. A payer substituting biosimilar pricing onto a branded claim might actually overpay in those specific cases. Knowing which direction the substitution runs matters as much as knowing it happens at all.

NDC-level tracking is the tool that makes this visible. When the NDC on a claim clearly identifies the branded product but the payer reprices it at biosimilar rates anyway, the discrepancy only becomes visible if someone is tracking paid rate against NDC. Skip that step, and the repricing passes through unnoticed.

Adalimumab, infliximab (J1745 against its biosimilar J-codes), and rituximab (J9312) sit at the center of this exposure, which makes rheumatology and gastroenterology practices disproportionately vulnerable. White-bagging trends compound the pressure: in 2022, 27% of oncology therapy products administered in physician offices were subject to white-bagging requirements under commercial insurance. Payers pushing white-bagging are partly chasing the same biosimilar savings they'd otherwise miss through substitution pricing. Practices holding onto buy-and-bill face both risks at once: substitution pricing on one side, shrinking volume from white-bagging policy on the other.

Contractual misapplication, when the payer's payment doesn't match the negotiated rate

Payers keep fee schedules inside adjudication systems that update on their own timeline, separate from whenever a contract actually gets amended. A negotiated rate increase can sit finalized on paper for months without ever reaching the system that prices the claim. That lag is the whole problem, and it's entirely on the payer's side to fix, though nobody fixes it without pressure.

Place-of-service coding adds another layer. Place of Service 11 (physician office) and Place of Service 22 (outpatient hospital) generate different Medicare Part B rates for the identical J-code. A mismatch between how the claim gets filed and how the payer's system reads it produces the wrong rate, silently. CMS extended site-neutral payment policy under the CY2026 OPPS and ASC Final Rule to physician-administered drug services, meaning identical services now reimburse differently depending on where, and under which billing entity, they're filed. Practices running multiple sites face real exposure if site-of-service coding isn't kept airtight and consistent.

Run ten or more payer contracts, each with its own J-code-specific rates, and the odds that at least one system somewhere is running a stale or wrong rate at any given moment run high. That error only ever surfaces through contract-level, J-code-level reconciliation between expected payment and actual payment. Nothing else finds it.

Denial-rate metrics won't catch it either. Underpayments never enter the denial queue. They post as paid claims, which makes them structurally invisible to any workflow built around managing denials. In a multi-specialty group running ten payer contracts, uncorrected contractual misapplications can represent a meaningful share of total annual collections, a figure that compounds every year it goes unrecovered.

340B adds one more layer of rate risk. Qualifying infusion centers use the JG modifier for 340B drugs and TB for non-340B drugs, and a modifier error shifts which reimbursement schedule the payer applies. Get it wrong, and the result is either an underpayment or a compliance finding, sometimes both.

Why line-level remittance review is rarely performed where underpayments live

Most remittance review happens at the claim level or the aggregate level: total paid against total billed, with most of the attention going to denials and zero-pay lines. That's where the visible fires are. It's also why underpayments survive.

An underpayment posts as a paid claim with a contractual adjustment attached. It clears the denial queue, gets marked closed, and the underpaid amount gets written off as if it were a completely legitimate reduction. Nobody reopens a claim that already says "paid."

Catching a J-code-level underpayment takes four things at once: knowing the correct current-quarter ASP for that specific drug, knowing the contracted rate that specific payer owes for that specific J-code, reconciling units billed against units actually paid, and recognizing when a bundling adjustment has no clinical justification behind it. That's four reference points, held simultaneously, and aggregate remittance tools don't display any of them together.

Revenue cycle reporting reinforces the blind spot. initial claim denial rates hit 11.81% across more than 2,100 hospitals and 300,000 physicians in 2024, and once claims pass 120 days outstanding, recovery rates fall below 40%. Those numbers measure denials and speed. None of them measure accuracy, and slower payment and systematically wrong payment are two different problems that the same AR metric can't tell apart.

The missing piece is payer-specific pattern recognition. Denial patterns run payer-specific and root-cause-specific, and underpayment patterns follow that exact same logic. A payer that consistently misapplies the biosimilar rate on adalimumab claims will keep doing it, claim after claim, until someone notices. That consistency is the signal a practice needs, both to recover what's already gone and to stop losing more, but it becomes visible only when claims get analyzed at the J-code-and-payer level, not folded into a general ledger. Skip that line-level reconciliation, and underpayments turn into permanent write-offs, because once the remittance posts, there's no way left to tell a legitimate contractual adjustment apart from an erroneous one.

Building a remittance review process that catches underpayments before they close

Fixing this starts at claim construction, not at the remittance. Revenue cycle control begins at scheduling and coding, because by the time a remittance lands, the unit count, the J-code, the NDC, and the modifiers are already locked in. Review at that point can catch errors, but it can't undo decisions made weeks earlier. Treating remittance review as the first line of defense is the mistake most practices make, and it's backwards.

Before remittances even arrive, practices need a live J-code rate sheet, updated every time CMS releases a new quarterly ASP, listing the correct expected payment for every drug billed, broken out by payer. That sheet becomes the reference point every paid amount gets checked against, not a guess, not last quarter's number.

At the posting stage, any claim where the paid amount differs from the expected amount by more than a set tolerance needs a flag. High-dollar J-code lines shouldn't get auto-written-off as routine contractual adjustments without a person confirming the adjustment is actually legitimate first.

And every underpayment that does get caught should go into a running log, broken out by payer name, J-code, and underpayment type, whether that's ASP lag, unit reduction, biosimilar substitution, bundling, or contractual misapplication. Patterns that repeat across that log are systemic issues, not one-off mistakes, and systemic issues are what contract disputes and payer outreach exist to fix. The individual errors run small. The pattern is where the money actually sits.